Oncology Medical News about Venous Thromboembolism Heparin

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism
Cochrane Reviews, 10/09/09

Vardi M et al. – Fifteen randomised controlled trials were identified that included a total of 1475 patients in the intervention group and 1579 patients in the control group. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism cannot be considered non–inferior to other treatment modalities in terms of recurrent DVT and PE at three months, but seems as safe and effective with regards to rates of major bleeding and death.

<< Previous
Surgical excision margins for primary cutaneous melanoma

Next >>
Effectiveness of a balance training home exercise programme for...